Data Insights

Pegadricase by Swedish Orphan Biovitrum for Gouty Arthritis (Gout): Likelihood of Approval

Pegadricase is under clinical development by Swedish Orphan Biovitrum and currently in Pre-Registration for Gouty Arthritis (Gout). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pegadricase in Gouty Arthritis (Gout)

Data Insights

Anakinra by Swedish Orphan Biovitrum for Hospital Acquired Pneumonia (HAP): Likelihood of Approval

Anakinra is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Hospital Acquired Pneumonia (HAP). According...

Likelihood of Approval and Phase Transition Success Rate Model - Anakinra in Hospital Acquired Pneumonia (HAP)

Data Insights

Anakinra by Swedish Orphan Biovitrum for Community Acquired Pneumonia: Likelihood of Approval

Anakinra is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Community Acquired Pneumonia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Anakinra in Community Acquired Pneumonia

Data Insights

Anakinra by Swedish Orphan Biovitrum for Cytokine Release Syndrome (Cytokine Storm): Likelihood of Approval

Anakinra is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Cytokine Release Syndrome (Cytokine Storm)....

Likelihood of Approval and Phase Transition Success Rate Model - Anakinra in Cytokine Release Syndrome (Cytokine Storm)

Data Insights

Loncastuximab tesirine by Swedish Orphan Biovitrum for Post-Transplant Lymphoproliferative Disorder: Likelihood of Approval

Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Post-Transplant Lymphoproliferative Disorder. According...

Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Post-Transplant Lymphoproliferative Disorder

Data Insights

Loncastuximab tesirine by Swedish Orphan Biovitrum for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Splenic Marginal Zone B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Splenic Marginal Zone B-Cell Lymphoma

Data Insights

Loncastuximab tesirine by Swedish Orphan Biovitrum for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Extranodal Marginal Zone B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)

Data Insights

Loncastuximab tesirine by Swedish Orphan Biovitrum for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Marginal Zone B-cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Marginal Zone B-cell Lymphoma

Data Insights

Loncastuximab tesirine by Swedish Orphan Biovitrum for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Loncastuximab tesirine by Swedish Orphan Biovitrum for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Data Insights

Loncastuximab tesirine by Swedish Orphan Biovitrum for Burkitt Lymphoma: Likelihood of Approval

Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Burkitt Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Burkitt Lymphoma

Data Insights

Loncastuximab tesirine by Swedish Orphan Biovitrum for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in B-Cell Non-Hodgkin Lymphoma

Data Insights

Anakinra by Swedish Orphan Biovitrum for Sepsis: Likelihood of Approval

Anakinra is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Sepsis. According to GlobalData, Phase...

Data Insights

Emapalumab by Swedish Orphan Biovitrum for Cytopenia: Likelihood of Approval

Emapalumab is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Cytopenia. According to GlobalData, Phase...

Data Insights

Emapalumab by Swedish Orphan Biovitrum for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease): Likelihood of Approval

Emapalumab is under clinical development by Swedish Orphan Biovitrum and currently in Phase III for Systemic-Onset Juvenile Idiopathic Arthritis (Still...

Data Insights

Anakinra by Swedish Orphan Biovitrum for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ): Likelihood of Approval

Anakinra is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Mucopolysaccharidosis III (MPS III) (Sanfilippo...